Thank you to Mr Kamal Lakhdar (Moroccan painter) for the generous painting that represents tumor heterogeneity: the thread connecting the research of our team!

Molecular biologist by training, Charly splits his studies between the University of Rennes 1 and Lyon 1 in France. After a master degree in molecular and cellular oncology, he started a 3 years PhD at the IRSET Institute, in Rennes, under the supervision of Dr Denis Michel. His research focused on estrogen receptor alpha and aimed to better understand how micro environmental hypoxia can drive hormone resistance in breast cancer cells. He also identified MKL1, a transcriptional co-activator activated after E-Cadherin disruption, capable of converting epithelial luminal to basal cell identity, thereby enhancing tumor cell malignancy. After defending his PhD last December, Charly left the softness of Brittany for this exciting challenge as Post-doc in Momo’s lab where he will be working on epigenetic mechanisms underpinning tumor cell heterogeneity and anti-cancer drug resistance.

We wish you success in the next steps of your career. Joana Silva joint Novartis Oncology in Basel and Milan Obradovic joined Wellmera AG in Basel.

Thank you all for making it a great and successful venture: www.enbdc.org.

The 10th annual ENBDC workshop with about 70 participants from Switzerland and other European countries took place on March 15-­17, 2018 in Weggis.

Milica Vulin received the prize for the best poster for her PhD work.

http://www.enbdc.org/

Swiss personalized Oncology: Our goal is to create a world-class multidisciplinary center for translational research in Personalized Health medicine in the cancer field.

https://www.unibas.ch/en/Focal-areas/Personalized-Health-Basel/Research/PHB-Oncology-Cluster.html